Ectodysplasin A2 Receptor antibody

Catalog No. ABIN501133

Product Details anti-Ectodysplasin A2 Receptor Antibody

Target: Ectodysplasin A2 Receptor (EDA2R)

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Ectodysplasin A2 Receptor antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Specificity: This antibody detects EDA2R / TNFRSF27.

Cross-Reactivity (Details): Species reactivity (tested):Human

Purification: Affiinity chromatography

Immunogen: XEDAR antibody was raised against recombinant human XEDAR.

Isotype: IgG

Application Details

Application Notes: ELISA. Western blot: 0.5 - 1 μg/mL. Immunohistochemistrry on paraffin sections.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Buffer: PBS containing 0.02 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Store at 2 - 8 °C for up to one month or (in aliquots) at -20 °C for longer.

Target Details for Ectodysplasin A2 Receptor

Target: Ectodysplasin A2 Receptor (EDA2R)

Alternative Name: EDA2R / TNFRSF27 (EDA2R Products)

Synonyms: EDA-A2R antibody, EDAA2R antibody, TNFRSF27 antibody, XEDAR antibody, 9430060M22Rik antibody, Xedar antibody, RGD1564025 antibody, ectodysplasin A2 receptor antibody, EDA2R antibody, Eda2r antibody

Background: X-linked ectodysplasin-A2 receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplatin-A2 (EDA-A2) (1). Two predominantly expressed isoforms, XEDAR-s and XEDAR-L, differ by only a 21-amino region at the juxtamembrane region of the cytoplasmic domain. Neither isoform possesses a death domain and both have been shown to act mainly through TRAF3 and TRAF6 to activate the NF-kappaB and JNK pathways (2). Cells transfected with XEDAR and treated with EDA-A2 cause the assembly of a secondary complex containing FADD, caspase-8 and caspase-10, leading to the activation caspase-8 and caspase-3, and finally apoptosis (3). The EDA-A2-induced apoptosis is dependent on caspase-9 activation, as various pharmacological and genetic inhibitors of caspase-8 blocked apoptosis following EDA-A2 treatment (3).Synonyms: EDA-A2 receptor, Tumor necrosis factor receptor superfamily member 27, UNQ2448/PRO5727/PRO34080, X-linked ectodysplasin-A2 receptor, XEDAR

Gene ID: 60401